Abazistobart
Abazistobart is an immunostimulant and antineoplastic agent targeting the programmed cell death protein 1 (PDCD1) . Abazistobart is a chimeric and humanized monoclonal antibody that specifically binds to PDCD1 to block the relevant signaling pathway, thereby activating the immune system and exerting antineoplastic activity. Abazistobart is promising for research of cancers[1].
Product Specifications
CAS Number
3002062-67-8
UNSPSC
12352203
Target
PD-1/PD-L1
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Smiles
[Abazistobart]
References & Citations
[1]World Health Organization. WHO Drug Information: Volume 38[M]. World Health Organization, 2024.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog